Cargando…
The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review
Nearly 35 million people worldwide live with Alzheimer’s disease (AD). The prevalence of the disease is expected to rise two-fold by 2050. With only symptomatic treatment options available, it is essential to understand the developments and existing evidence that aims to target brain pathology and d...
Autores principales: | Rasheed, Anum, Zaheer, Ahmad Bin, Munawwar, Aqsa, Sarfraz, Zouina, Sarfraz, Azza, Robles-Velasco, Karla, Cherrez-Ojeda, Ivan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866790/ https://www.ncbi.nlm.nih.gov/pubmed/36675950 http://dx.doi.org/10.3390/life13010001 |
Ejemplares similares
-
The Evaluation of Inflammatory Biomarkers in Predicting Progression of Acute Pancreatitis to Pancreatic Necrosis: A Diagnostic Test Accuracy Review
por: Asim Riaz, Hafiz Muhammad, et al.
Publicado: (2022) -
Efficacy of Different Dosing Regimens of IgE Targeted Biologic Omalizumab for Chronic Spontaneous Urticaria in Adult and Pediatric Populations: A Meta-Analysis
por: Manzoor, Humayun, et al.
Publicado: (2022) -
Indicators of Climate Change, Geospatial and Analytical Mapping of Trends in India, Pakistan and Bangladesh: An Observational Study
por: Falak, Faiqa, et al.
Publicado: (2022) -
Addressing the Endometriosis Knowledge Gap for Improved Clinical Care—A Cross-Sectional Pre- and Post-Educational-Intervention Study among Pakistani Women
por: Saad, Muhammad, et al.
Publicado: (2023) -
Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials
por: Rashad, Areeba, et al.
Publicado: (2022)